Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trialRom S. Leidner, Bernard A. Fox, William L. Redmond et al.|Cancer Research|2024Cited by 3
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodiesDavid A. Knorr, Jeffrey V. Ravetch, Rom S. Leidner et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 2
The responses of HNSCC patients to immunotherapy are shown by two novel co-expression patternsNarmeen Daher-Ghanem, Nataly Kravchenko‐Balasha, Shay Sharon et al.|npj Precision Oncology|2025Cited by 2
113 Uncovering the dark immunopeptidome of head and neck squamous cell carcinoma (HNSCC): relevance for universal cancer vaccines, immunological monitoring and TIL therapyNoriko Iwamoto, Bernard A. Fox, Takashi Shimada et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1
148 Characterizing cancer’s dark matter, short-lived proteins, and defective ribosomal products, presented by cancer and contained in the DPV-001 cancer vaccineRyan Meng, Bernard A. Fox, Tarsem Moudgil et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1